8 completed, 3 recruiting, 3 terminated, 2 not yet recruiting. 18 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 8, Recruiting 3, Terminated 3, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow mitoquinone: new trials by email Literature Review of mitoquinone trials Research Report on mitoquinone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MitoQ Supplementation for Microvascular Health and Stroke Recovery MitoQ, Placebo - Stroke, Stroke Recurrence | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 50 | 2027-01-01 | 2026-11-16 |
| Efficacy and Safety of MitoQ in Improving Cancer Cachexia MitoQ (mitoquinol mesylate) - Cancer Cachexia (CC), Cancer Patients With Solid Tumors | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 20 | 2026-10-10 | 2026-09-23 |
| Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis MitoQ, Placebo - Ulcerative Colitis | Phase 2 | Withdrawn | University of Edinburgh | 2025-09-01 | 2026-01-09 | |
| The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults Mitoquinone Mesylate, Placebo capsule - Frailty, Mild Cognitive Impairment | Phase 2 | Recruiting | UConn Health | 60 | 2024-10-07 | 2026-08-12 |
| Effects of an Antioxidant Supplement on Blood Vessel Health MitoQ, Placebo, MitoTempo - Healthy | Phase 2 | Recruiting | University of Georgia | 60 | 2024-07-01 | 2024-12-09 |
| ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments Astaxanthin, Protandim, Melatonin - Amyotrophic Lateral Sclerosis ALS | Phase 2 | Completed | Duke University | 50 | 2024-06-12 | 2026-10-27 |
| MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction MitoQ, Placebo - Schizophrenia and Related Disorders, Mitochondrial Alteration | Phase 2 / Phase 3 | Recruiting | Mclean Hospital | 100 | 2024-06-01 | 2025-09-25 |
| Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome MitoQ (mitoquinol mesylate), Placebo - Lower Urinary Tract Symptoms, Overactive Bladder Syndrome | Phase 2 | Terminated | Iman Al-Naggar, PhD | 20 | 2024-04-03 | 2026-05-01 |
| Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 Mitoquinone/mitoquinol mesylate, Placebo - SARS-CoV Infection, COVID-19 | Phase 2 | Completed | University of Texas Southwestern Medical Center | 122 | 2024-03-01 | 2026-09-21 |
| Examining the Effects of Mitochondrial Oxidative Stress in DCM MitoQ Compound, Placebo - Dilated Cardiomyopathy | Phase 2 | Completed | Imperial College London | 53 | 2022-07-26 | 2025-09-18 |
| MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis MitoQ, Placebo - Ulcerative Colitis Flare | Phase 2 | Active not recruiting | University of Edinburgh | 79 | 2022-05-31 | 2026-01-13 |
| An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness Mitoquinone/mitoquinol mesylate - Respiratory Viral Infection, Antiviral Treatment | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 80 | 2022-04-28 | 2025-12-16 |
| Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans MitoQ, Placebo - Aging | Phase 2 | Completed | University of Colorado, Boulder | 112 | 2021-04-02 | 2026-08-05 |
| MitoQ for Fatigue in Multiple Sclerosis (MS) 20 mg MitoQ, Placebo, 40mg of MitoQ - Multiple Sclerosis, Fatigue | Phase 1 / Phase 2 | Completed | VA Office of Research and Development | 45 | 2020-04-01 | 2026-04-24 |
| MitoQ for Fatigue in Multiple Sclerosis Mitoquinone, Placebo - Multiple Sclerosis, Fatigue | Phase 1 / Phase 2 | Terminated | Oregon Health and Science University | 9 | 2018-09-15 | 2023-04-05 |
| A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD) Mitoquinone mesylate, Placebo - Non-alcoholic Fatty Liver Disease | Phase 2 | Terminated | Antipodean Pharmaceuticals, Inc. | 110 | 2010-11-01 | 2011-06-01 |
| Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C Mitoquinone mesylate (MitoQ) - Chronic Hepatitis C | Phase 2 | Completed | Antipodean Pharmaceuticals, Inc. | 30 | 2007-03-01 | 2008-08-14 |
| A Trial of MitoQ for the Treatment of People With Parkinson's Disease MitoQ - Parkinson's Disease | Phase 2 | Completed | Antipodean Pharmaceuticals, Inc. | 128 | 2006-05-01 | 2010-07-21 |
COVID-19 (2) · Cognitive Dysfunction (2) · Fatigue (2) · Multiple Sclerosis (2) · Amyotrophic Lateral Sclerosis (1) · Cardiomyopathy, Dilated (1) · Cardiovascular Diseases (1) · Colitis, Ulcerative (1) · Frailty (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Hypertension (1) · Lower Urinary Tract Symptoms (1) · Metabolic Syndrome (1) · Non-alcoholic Fatty Liver Disease (1)
Antipodean Pharmaceuticals, Inc. (3) · University of Edinburgh (2) · Duke University (1) · Iman Al-Naggar, PhD (1) · Imperial College London (1) · Mclean Hospital (1) · Medical College of Wisconsin (1) · Oregon Health and Science University (1) · The First Affiliated Hospital of Xinxiang Medical College (1) · UConn Health (1) · University of California, Los Angeles (1) · University of Colorado, Boulder (1) · University of Georgia (1) · University of Texas Southwestern Medical Center (1) · VA Office of Research and Development (1)
United States (11) · United Kingdom (4) · New Zealand (2) · Australia (1) · Switzerland (1)
Barry J Snow, MD (1) · Brian Halliday, MBChB PhD (1) · Chris Day, MD, PhD (1) · David Wilson, MD (1) · Dost Ongur, MD, PhD (1) · Douglas R Seals (1) · Edward J Gane, MBChB (1) · Iman M Al-Naggar, PhD (1) · Matthew Durand, PhD (1) · Oh Sung Kwon, PhD (1) · Theodoros Kelesidis, MD PHD (1) · Theodoros Kelesidis, MD, PHD, Msc (1) · Vijayshree Yadav, MBBS (1) · Vijayshree Yadav, MD (1)
PMID 20492507, PMID 36187760, PMID 38471990, PMID 40603760, PMID 41264372
K01AG080164 (1), P30AG067988 (1), R01AG066730 (1)